prohibited list comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-28. Numbers and descriptions here follow the published literature rather than marketing material.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
The amino acids that make up a particular helix can be plotted on a helical wheel, a representation that illustrates the orientations of the constituent amino acids (see the article for leucine zipper for such a diagram). Often in globular proteins, as well as in specialized structures such as coiled-coils and leucine zippers, an α-helix will exhibit two "faces" – one containing predominantly hydrophobic amino acids oriented toward the interior of the protein, in the hydrophobic core, and one containing predominantly polar amino acids oriented toward the solvent-exposed surface of the protein. Changes in binding orientation also occur for facially-organized oligopeptides. This pattern is especially common in antimicrobial peptides, and many models have been devised to describe how this relates to their function. Common to many of them is that the hydrophobic face of the antimicrobial peptide forms pores in the plasma membrane after associating with the fatty chains at the membrane core.
=== Radiation side-effects === Diagnostic treatment involving technetium-99m will result in radiation exposure to technicians, patients, and passers-by. Typical quantities of technetium administered for immunoscintigraphy tests, such as SPECT tests, range from 400 to 1,100 MBq (11 to 30 mCi) (millicurie or mCi; and Mega-Becquerel or MBq) for adults. These doses result in radiation exposures to the patient around 10 mSv (1000 mrem), the equivalent of about 500 chest X-ray exposures. This level of radiation exposure is estimated by the linear no-threshold model to carry a 1 in 1000 lifetime risk of developing a solid cancer or leukemia in the patient. The risk is higher in younger patients, and lower in older ones. Unlike a chest x-ray, the radiation source is inside the patient and will be carried around for a few days, exposing others to second-hand radiation. A spouse who stays constantly by the side of the patient through this time might receive one thousandth of patient's radiation dose this way. The short half-life of the isotope allows for scanning procedures that collect data rapidly. The isotope is also of a very low energy level for a gamma emitter. Its ~140 keV of energy make it safer for use because of the substantially reduced ionization compared with other gamma emitters. The energy of gammas from 99mTc is about the same as the radiation from a commercial diagnostic X-ray machine, although the number of gammas emitted results in radiation doses more comparable to X-ray studies like computed tomography.
=== Biosimilars === Abasaglar was authorized for medical use in the European Union in September 2014. Lusduna was authorized for medical use in the European Union in January 2017. Semglee was authorized for medical use in the European Union in March 2018. Semglee (glargine-yfgn) was approved for medical use in the United States in July 2021. Rezvoglar (glargine-aglr) was approved for medical use in the United States in December 2021. In November 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ondibta, intended for the treatment of diabetes. The applicant for this medicinal product is Gan & Lee Pharmaceuticals Europe GmbH. Ondibta is a biosimilar medicinal product that is highly similar to the reference product Lantus, which was authorized in the EU in June 2000. Ondibta was authorized for medical use in the European Union in January 2026.
"Life Goes On" (Russian: «Жизнь продолжается») is an article published in the 3 September 2008 issue of the Russian Ministry of Defence's official newspaper, Krasnaya Zvezda. It was also posted on the newspaper's web site. The article was based on the interview of an officer who had taken part in the military operation in South Ossetia in August 2008. The article details the war experience of Russian captain of the 135th regiment named Denis Sidristy. Sidristy's unit was sent to Tskhinvali on 7 August, and he was there when the hostilities broke out. Sidristy said that he saw the Georgian military assault around midnight. After the initial publication, it was picked up by blogs and internet news agencies, as it contradicted the official timeline of Russian incursion into South Ossetia. However, the article was later corrected and the date of the order to deploy to Tskhinvali was now given as the night of 7 August. Soon, the article was pulled from the newspaper's web site, having been commented upon by the mainstream media, including The New York Times. After a query by The New York Times about the article, Krasnaya Zvezda later published an article in which Captain Sidristy said the accurate date was August 8, not August 7.
==== Majors and programs ==== Doctoral Communication Sciences and Disorders Audiology Physical Therapy Master's Communication Sciences and Disorders Speech-language Pathology Genetic Counseling Health Administration (in conjunction with the College of Medicine and the Lindner College of Business) Nutrition Sciences Transfusion and Transplantation Services Bachelor's Advanced Medical Imaging Technology Clinical Laboratory Science Clinical Laboratory Science – Distance Learning Communication Sciences and Disorders Dietetics Food and Nutrition Concentration in Exercise Science Concentration in Pre-Medicine Health Information Management – Distance Learning Health Sciences Sports and Biomechanics Concentration Exercise Science Concentration Certificate Clinical Laboratory Science Dietetics School of Social Work
Sources: en.wikipedia.org
=== Pharmacodynamics === Esketamine is approximately twice as potent an anesthetic as racemic ketamine. The possibility that arketamine may be more effective than esketamine has been suggested by some researchers. Esketamine inhibits dopamine transporters eight times more than arketamine. This increases dopamine activity in the brain. At doses causing the same intensity of effects, esketamine is generally considered to be more pleasant by patients. Patients also generally recover mental function more quickly after being treated with pure esketamine, which may be a result of the fact that it is cleared from their system more quickly. However, this observation contrasts with findings that arketamine exhibits antidepressant effects without causing psychotomimetic side effects. Unlike arketamine, esketamine does not bind significantly to sigma receptors. Esketamine increases glucose metabolism in the frontal cortex, while arketamine decreases glucose metabolism in the brain. This difference may be responsible for the fact that esketamine generally has a more dissociative or hallucinogenic effect while arketamine is reportedly more relaxing. However, another study found no difference between racemic ketamine and esketamine on the patient's level of vigilance. Interpretation of this finding is complicated by the fact that racemic ketamine is 50% esketamine.
== External links == A primer on "Immunotherapy to Treat Cancer", NIH Immunotherapy – Using the Immune System to Treat Cancer. Archived 4 April 2017 at the Wayback Machine Cancer Research Institute – What is Cancer Immunotherapy. Archived 26 January 2017 at the Wayback Machine Association for Immunotherapy of Cancer Society for Immunotherapy of Cancer "And Then There Were Five". Economist. "Discover the Science of Immuno-Oncology". Bristol-Myers Squibb. Archived from the original on 10 October 2014. Retrieved 13 March 2014. Eggermont A, Finn O (September 2012). "Advances in immuno-oncology. Foreword". Annals of Oncology. 23 (Suppl 8): viii5. doi:10.1093/annonc/mds255. PMID 22918929. "Cancer Immunotherapy in Gujarat"
=== Purpose === All food grown or killed by the Inca could be freeze dried. Freeze drying is still very popular today. One of the biggest benefits for freeze-drying is that it takes out all of the water and moisture but leaves all of the nutritious value. The water in meats and vegetables is what gives them a lot of their weight. This is what made it very popular for transportation purposes and storage because dried meats lasted twice as long as non-freeze-dried foods.
== Chemistry == L-DOPA, also known as L-3,4-dihydroxyphenylalanine or L-3-hydroxytyrosine, is an aromatic amino acid derived from L-phenylalanine and L-tyrosine. It is a phenethylamine, monoamine, and catecholamine, and is a biological precursor of the neurotransmitters dopamine (3,4-dihydroxyphenethylamine), norepinephrine (3,4,β-trihydroxyphenethylamine), and epinephrine (3,4,β-trihydroxy-N-methylphenethylamine).
Sources: en.wikipedia.org
== Contraindications == Circumcision is contraindicated in certain cases. These include infants with certain genital structure abnormalities, such as a misplaced urethral opening (as in hypospadias and epispadias), curvature of the head of the penis (chordee), or ambiguous genitalia, because the foreskin may be needed for reconstructive surgery. Circumcision is contraindicated in premature infants and those who are not clinically stable and in good health. If a person is known to have or has a family history of serious bleeding disorders such as hemophilia, it is recommended that the blood be checked for normal coagulation properties before the procedure is attempted.
1885: Berries from Norfolk, Virginia, were shipped by refrigerator car to New York. 1887: Parker Earle joined F.A. Thomas of Chicago in the fruit shipping business. The company owned 60 ice-cooled railcars by 1888, and 600 by 1891. 1888: Armour & Co. shipped beef from Chicago to Florida in a car cooled by ethyl chloride-compression machinery. Florida oranges were shipped to New York under refrigeration for the first time. 1889: The first cooled shipment of fruit from California was sold on the New York market. 1898: Russia's first refrigerator cars entered service. The country's inventory reached 1,900 by 1908, 3,000 two years later, and peaked at approximately 5,900 by 1916. The cars were used mainly for transporting butter from Siberia to the Baltic Sea, a 12-day journey. 1899: Refrigerated fruit traffic within the U.S. reached 90,000 short tons (81,647 t; 80,357 long tons) per year; Transport from California to New York averaged 12 days in 1900. 1901: Carl von Linde equipped a Russian train with a mobile, central mechanical refrigeration plant to distribute cooling to cars carrying perishable goods. Similar systems were used in Russia as late as 1975. 1905: U.S. traffic in refrigerated fruit reached 430,000 short tons (390,089 t; 383,929 long tons). As refrigerator car designs became standardized, the practice of indicating the "patentee" on the sides was discontinued. 1907: The Pacific Fruit Express began operations with more than 6,000 refrigerated cars, transporting fruit and vegetables from Western producers to Eastern consumers. U.S.
== Civilian use == MREs have also been distributed to civilians during natural disasters. The National Guard has provided MREs to the public during natural disasters, such as Hurricanes Katrina, Ike, Maria and Sandy; and the 2011 Super Outbreak. The large number of civilians exposed to MREs prompted several jokes during the recent Mardi Gras in New Orleans, with revellers donning clothing made of MRE packets with phrases such as "MRE Antoinette" (referring to Marie Antoinette; the wife of King Louis XVI) and "Man Ready to Eat". The use of rations for noncombat environments has been questioned. While the nutritional requirements are suitable for a combat environment where servicemembers will burn many calories and lose much sodium through sweat, it has been provided as emergency food or even as a standard meal. The high-fat (averaging about 52 grams of fat, 5 grams trans fats) and high-salt content (averaging about 2 grams) are less than ideal for sedentary situations. In the aftermath of Hurricane Katrina, a 77-year-old civilian man with prior congestive heart failure ended up with volume overload from the high sodium content of MREs. The HDR and TOTM account for this nutritional need. Civilian taste-testing of MREs is popular. For example, the YouTuber known as Steve1989MREInfo reviews MREs and other rations from the U.S. or other countries (such as the Individual Meal Pack), as well as vintage rations like the K-ration for content on YouTube. He gives comprehensive reviews and information about each ration he has.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.